TELA Bio Announces Leadership Change with New President

TELA Bio ( (TELA) ) has shared an announcement.

On May 30, 2025, TELA Bio announced the resignation of Jeffrey Blizard from its Board of Directors, effective June 2, 2025, as he transitions to the role of President. This strategic leadership change is expected to enhance TELA Bio’s growth trajectory, with Blizard bringing extensive industry experience from his previous role at Abiomed, a Johnson & Johnson company. The appointment is seen as a significant step in strengthening the company’s executive team to drive commercial performance and value delivery to stakeholders.

The most recent analyst rating on (TELA) stock is a Buy with a $12.00 price target. To see the full list of analyst forecasts on TELA Bio stock, see the TELA Stock Forecast page.

Spark’s Take on TELA Stock

According to Spark, TipRanks’ AI Analyst, TELA is a Neutral.

TELA Bio’s score is primarily driven by solid revenue growth and positive earnings call sentiment, despite financial challenges like operational losses and high leverage. Technical indicators show short-term bullish potential, but valuation metrics are weak due to unprofitability.

To see Spark’s full report on TELA stock, click here.

More about TELA Bio

TELA Bio, Inc. is a commercial-stage medical technology company specializing in innovative soft-tissue reconstruction solutions. The company focuses on optimizing clinical outcomes by preserving and restoring the patient’s own anatomy, providing advanced and economically effective solutions that leverage natural healing responses while minimizing exposure to permanent synthetic materials.

Average Trading Volume: 261,270

Technical Sentiment Signal: Sell

Current Market Cap: $54.98M

For a thorough assessment of TELA stock, go to TipRanks’ Stock Analysis page.